Research and Markets has announced the addition of the "Dyslipidemia - Pipeline Review, H2 2016" report to their offering.
Dyslipidemia pipeline therapeutics constitutes close to 127 molecules, out of which approximately 111 molecules are developed by Companies and the remaining by the Universities/Institutes.
Dyslipidemia - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood, such as genetic predisposition, diet, age and gender, and type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.
The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 19, 17, 15, 3, 45, 5 and 3, respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 14 and 1 molecules, respectively.
Furthermore, this report also reviews key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/blhdhs/dyslipidemia.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161003006339/en/Business Wire
Last updated on: 03/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.